VivoSeq
Oncology

Stomach Cancer

0

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Stomach Cancer is an early-stage landscape with 0 programs across 5 companies. The most active players are Bristol-Myers Squibb, Daiichi Sankyo, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalE

Eastern Cooperative Oncology Group

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Completed20 · 83%
Terminated4 · 17%

Clinical Trials

Trial Activity

24 trials

DX-8951f in Treating Patients With Metastatic Stomach Cancer
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT00017212
Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer
Completed·Sanofi logoSanofi·Phase 3·NCT00411229·1,035 enrolled
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer
Completed·VVanderbilt University·Phase 1·NCT00477880·9 enrolled
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00017056
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00006389·12 enrolled
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201747·80 enrolled
S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer
Completed·KKyoto University·Phase 3·NCT00182611·100 enrolled
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Completed·—·Phase 1·NCT00446290·22 enrolled
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003172
Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
Completed·MMedical Research Council·Phase 3·NCT00002615·500 enrolled
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00003748·40 enrolled
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT02872116·2,031 enrolled
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
Completed·NNYU Langone Health·Phase 2·NCT00004103
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Completed·Eli Lilly logoEli Lilly·Phase 3·NCT02314117·645 enrolled
High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00002722·135 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)